PHARMACOKINETICS AND SAFETY OF ELAFIBRANOR IN SUBJECTS WITH IMPAIRED HEPATIC FUNCTION

被引：0
|
作者：
Noel, Benoit [1 ]
Vargas, Dawn [2 ]
Georges-Coty, Anne [1 ]
Roudot, Alice [1 ]
Roux, Olivier [3 ]
Magrez, David [1 ]
Wyatt, David [4 ]
Birman, Pascal [1 ]
Addy, Carol [1 ,5 ]
机构：
[1] Genfit SA, Loos, France
[2] Genfit CORP, Loos, France
[3] It&m Stats, Neuilly Sur Seine, France
[4] Syneos Hlth, Morrisville, NC USA
[5] Genfit SA, Clin Dev, Loos, France
来源：
HEPATOLOGY | 2021年 / 74卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1287
引用
收藏
页码：772A / 773A
页数：2
相关论文
共 50 条
  • [21] Single-Dose Pharmacokinetics of Boceprevir in Subjects with Impaired Hepatic or Renal Function
    Michelle Treitel
    Thomas Marbury
    Richard A. Preston
    Ilias Triantafyllou
    William Feely
    Edward O’Mara
    Claudia Kasserra
    Samir Gupta
    Eric A. Hughes
    Clinical Pharmacokinetics, 2012, 51 (9) : 619 - 628
  • [22] The multiple dose pharmacokinetics of cilansetron in subjects with normal and impaired hepatic function.
    Pardue, RL
    Zipfel, L
    Fritsch, H
    Brennan, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) : P78 - P78
  • [23] PHARMACOKINETICS AND SAFETY OF TIAGABINE IN SUBJECTS WITH VARYING DEGREES OF HEPATIC-FUNCTION
    GUSTAVSON, LE
    QIAN, JX
    SAULIS, R
    CARLSON, GF
    LAU, A
    SPERELAKIS, R
    LAM, N
    RINGHAM, GL
    SOMMERVILLE, KW
    EPILEPSIA, 1995, 36 : S159 - S159
  • [24] PHARMACOKINETICS AND SAFETY OF A SINGLE ORAL DOSE OF PEFICITINIB (ASP015K) IN SUBJECTS WITH NORMAL AND IMPAIRED HEPATIC FUNCTION
    Miyatake, Daisuke
    Shibata, Tomohisa
    Toyoshima, Junko
    Kaneko, Yuichiro
    Oda, Kazuo
    Nishimura, Tetsuya
    Katashima, Masataka
    Sakaki, Masashi
    Inoue, Kazuaki
    Ito, Takayoshi
    Uchida, Naoki
    Furihata, Kenichi
    Urae, Akinori
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 752 - 753
  • [25] The single-dose pharmacokinetics of carisbamate in subjects with normal and impaired hepatic function.
    Moore, K. T.
    Zannikos, P.
    Solanki, B.
    Greenspan, A.
    Romano, G.
    Brashear, H.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S24 - S24
  • [26] Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects With Normal and Impaired Hepatic Function
    Miyatake, Daisuke
    Shibata, Tomohisa
    Toyoshima, Junko
    Kaneko, Yuichiro
    Oda, Kazuo
    Nishimura, Tetsuya
    Katashima, Masataka
    Sakaki, Masashi
    Inoue, Kazuaki
    Ito, Takayoshi
    Uchida, Naoki
    Furihata, Kenichi
    Urae, Akinori
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2020, 9 (06): : 699 - 708
  • [27] Pharmacokinetics of Dexrazoxane in Subjects With Impaired Kidney Function
    Brier, Michael E.
    Gaylor, Shari K.
    McGovren, J. Patrick
    Glue, Paul
    Fang, Annie
    Aronoff, George R.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (05): : 731 - 738
  • [28] Safety and Pharmacokinetics of Solithromycin in Subjects with Hepatic Impairment
    Jamieson, Brian D.
    Ciric, Sabrina
    Fernandes, Prabhavathi
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (08) : 4379 - 4386
  • [29] Pharmacokinetics and Safety of Teneligliptin in Subjects With Hepatic Impairment
    Halabi, Atef
    Maatouk, Haidar
    Siegler, Karl Ernst
    Faisst, Nadja
    Hinrichsen, Holger
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2014, 3 (04): : 290 - 296
  • [30] PHARMACOKINETICS AND SAFETY OF NITAZOXANIDE IN SUBJECTS WITH HEPATIC IMPAIRMENT
    Harisseh, Rania
    Finnegan, Beth
    Thomas, Stephane
    Legry, Vanessa
    Hum, Dean
    Marbury, Thomas C.
    Perry, Robert G.
    Wyatt, David J.
    Addy, Carol
    GASTROENTEROLOGY, 2023, 164 (06) : S1391 - S1391
12345